Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 702 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 Load more HOT NEWS Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC 6 things you need to know about cervical screening Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For...
